THE Therapeutic Goods
Administration has designated
Lucassin (terlipressin acetate) and
ATG-Fresenius (immunoglobulin -
antithymocyte) as orphan drugs.
Lucassin is sponsored by Ikaria
Australia and is indicated for the
treatment of patients with
hepatorenal syndrome type 1 and
for the treatment of oesophageal
variceal haemmorhage.
ATG-Fresenius’ sponsor is Dutec
Diagnostics Pty Ltd, and it’s
indicated for the prevention of graft
versus host disease in allogeneic
haematopoeitic stem cell
transplantation.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jul 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jul 10
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.